iejimalide B: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10985331 |
| CHEBI ID | 77759 |
| MeSH ID | M0510469 |
| Synonym |
|---|
| iejimalide b |
| CHEBI:77759 |
| n-{(2e,4e)-5-[(2s,3s,4e,6e,8s,11z,13e,16s,17e,19e,21r,22e)-8,16-dimethoxy-3,12,18,21,23-pentamethyl-24-oxooxacyclotetracosa-4,6,11,13,17,19,22-heptaen-2-yl]-2-methylhexa-2,4-dien-1-yl}-n(2)-formyl-l-serinamide |
| propanamide, n-((2e,4e)-5-((2s,3s,4e,6e,8s,11z,13e,16s,17e,19e,21r,22e)-8,16-dimethoxy-3,12,18,21,23-pentamethyl-24-oxooxacyclotetracosa-4,6,11,13,17,19,22-heptaen-2-yl)-2-methyl-2,4-hexadien-1-yl)-2-(formylamino)-3-hydroxy-, (2s)- |
| iejimalide b, (-)- |
| (2s)-n-[(2e,4e)-5-[(2s,3s,4e,6e,8s,11z,13e,16s,17e,19e,21r,22e)-8,16-dimethoxy-3,12,18,21,23-pentamethyl-24-oxo-1-oxacyclotetracosa-4,6,11,13,17,19,22-heptaen-2-yl]-2-methylhexa-2,4-dienyl]-2-formamido-3-hydroxypropanamide |
| Q27147352 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Iejimalide B, has a dose and time dependent effect on cell number (as measured by crystal violet assay) in both cell lines." | ( Effects of Iejimalide B, a marine macrolide, on growth and apoptosis in prostate cancer cell lines. Helquist, P; Jeffrey, R; McHenry, P; Schweitzer, D; Tenniswood, M; Wang, WL, 2008) | 1.46 |
| Role | Description |
|---|---|
| marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| macrolide | A macrocyclic lactone with a ring of twelve or more members derived from a polyketide. |
| ether | An organooxygen compound with formula ROR, where R is not hydrogen. |
| formamides | Amides with the general formula R(1)R(2)NCHO (R(1) and R(2) can be H). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||